As a mage, I just want to pursue the truth

Chapter 293 The incomprehensible style
Since its inception, biological storage technology has been considered to contain the secret of electronic immortality.

In the two years since China took the lead in releasing the biological storage server, many newly released science fiction works have used biological storage technology as a starting point, imagining that in the future human souls will be uploaded to biological storage servers.

In fact, souls and memories can indeed be uploaded, but this cannot be achieved through biological storage technology.

Moreover, even if the soul and memories are uploaded, immortality cannot be achieved.

"Mr. Li, the first batch of clinical trials has achieved very good results, even exceeding our expectations.

These five small molecules have extremely good effects on adult CM proliferation and cardiac regeneration.

At the same time, it can play a certain role in preventing coronary artery obstruction and precordial compression pain.

This is a phase I clinical trial report, a phase I report so far. You can take a look at it when you have time. "

After Wang Jinsong handed the report to Li Miaomiao, he left the other's office.

In fact, the relevant process can be completed entirely within the internal office system, and interim reports and interim results of the work can be sent to Li Miaomiao via corporate email.

But in order to leave a direct impression on the leader, it is also necessary to explain how effective their work is.

Face-to-face interviews are always more convincing than emails and can leave a deeper impression on leaders.

Especially now that the R&D team of innovative drugs has so many pipelines, only their group's new drugs have reached the clinical trial stage.

No matter what kind of company you are in, you must be able to do as well as speak. If you only know how to do, you cannot get promoted.

Even if it is just to gain more resources for your subordinates and assign fewer low-performance evaluation indicators at the end of the year, you need to report your work to your leaders more often.

As a returnee from overseas, Wang Jinsong did not understand this principle and suffered losses several times in the past.

Therefore, even if I am unwilling to do so, I will do it.

Under normal circumstances, Zheng Li would not meet with them, except at the annual meeting, when Zheng Li would give a speech via remote video link.

Apart from this, grassroots employees and even middle-level managers have no chance to meet Zheng Li.

The only way they could contact Zheng Li was through email.

Every employee of Kechuang Bio can send emails to Mr. Zheng, and the emails will be classified and processed by employees of the chairman's secretariat.

Reply, forward it to relevant persons or send it to Zheng Li via email.

In Zheng Li's opinion, there is no need to set up a department like a secretariat. BioCloud's artificial intelligence can handle these tasks perfectly.

In order not to appear special, the company set up a secretariat only after it had grown bigger.

Unlike Li Miaomiao and Zheng Li, middle-level employees can make an appointment to communicate with her privately in the internal system.

Li Miaomiao's secretary will make arrangements according to her wishes.

Li Miaomiao was very interested in the communication with Wang Jinsong this time, because what he said was not boring and he was able to clearly describe the work they did in a language that she could understand.

This is not easy, because the cutting-edge field of biomedicine is too professional, and it is very challenging for the reporter to make the presentation understandable to laymen.

However, this is also due to the improvement of Li Miaomiao's thinking ability.

If it were Li Miaomiao before using the magic brain, it would also be difficult for her to understand.

Apart from the senior management of CSPC, the people who are most concerned about the R&D progress of CSPC's innovative drugs are the shareholders who hold CSPC's shares.

They are even more concerned about the clinical trial results of innovative drugs than the executives of Sinovation Biotechnology who are not in charge of the innovative drug line.

“Does anyone know how the clinical trial results of Sinovation Biotech’s MSCS Type I drug are performing?
If this drug performs well in clinical trials, then the market value of Kechuang Biotechnology will be worth taking a step up.

Although Kechuang Bio was previously a leading company with a market value of trillions of dollars, it was actually extremely dependent on its founder Zheng Li.

Considering Zheng Li’s age, he is only 25 years old, which is the golden age for scientific research.

There are at least twenty-five years until I am fifty.

But I always feel that there are risks in a scientific research enterprise that relies on one person.

If Kechuang Biopharma makes a breakthrough in the field of innovative drugs, it will verify that Kechuang Biopharma's research and development team is trustworthy, adding an insurance for Kechuang Biopharma's scientific research capabilities.

Whether it is the official response from the secretary of the board of directors of Kechuang Bio or the speeches of Kechuang Bio executives on different occasions, it can be seen that Zheng Li has almost no involvement in the research and development of innovative drugs.

The drug that Kechuang Biopharma has invested in clinical stages this time is mainly aimed at treating heart cell failure.

This is a field with a vast market, and it is an area in which pharmaceutical giants from all over the world have invested huge resources to compete.

Although Pfizer has made rapid progress in research and development in this field in recent years, Sinopharm's innovative drugs still have their merits.

First of all, this is a drug that is a mixture of multiple small molecules, and it can also regenerate myocardial cells.

According to the "China Cardiovascular Health and Disease Report 2025" officially released by China, the number of people suffering from heart failure in my country alone was around million last year.

Once MSCS I performs well clinically, how huge will this market be?

More important than this market is the successful development of the R&D team of Kechuang Biotechnology.”

There is also a wizard behind Pfizer Pharmaceuticals, which has led to their drug research and development progress far exceeding expectations.

In fact, American's R&D investment in the biopharmaceutical field has been increasing.

Especially after the emergence of mages, America has invested half of its mages in the field of biomedicine.

Back to innovative drugs, Ke Chuang Biopharma originally chose the cardiovascular direction only for exploratory purposes.

At that time, I never thought about what results could really be achieved in this field.

Because there are too many competitors in this field and small molecule drugs have been screened many times, it is difficult to make a breakthrough.

It's like trying to pan for gold in a river where countless gold diggers have panned for gold. It's very difficult to find any.

Unexpectedly, this seemingly most difficult field was the first to produce results and enter the clinical trial stage.

In recent years, due to the prevalence of unhealthy diet, lack of physical activity, staying up late and smoking and other lifestyle factors, the absolute number of cardiovascular patients in China has continued to rise.

The direction chosen by Kechuang Bio has a broad market.

Of course, since there are too many patients in this field, it is inevitable that they will be included in the centralized procurement.

It's just a matter of time.

"Hello, Mr. Zheng, here is the phase I clinical trial report on the MSCS type I myocardial regeneration drug.

Myocardial infarction results in a massive loss of functional cardiomyocytes and is one of the leading causes of death in humans worldwide.

Although various methods such as drug therapy, thrombolysis, coronary artery stent implantation and coronary artery bypass grafting have been used clinically to treat myocardial infarction and improve patient survival rates, these methods cannot fundamentally repair the damaged heart and restore heart function.

Stem cell transplantation is considered a promising approach for the treatment of myocardial infarction.

Stem cell transplantation has made significant progress in preclinical and clinical research in recent years.

Stem cell candidates mainly include two categories: pluripotent stem cells and their derivatives, and adult stem cells including hematopoietic stem cells and mesenchymal stem cells.

Mesenchymal stem cells are mesoderm-derived multipotent stromal cells present in embryonic and adult tissues with the abilities of self-renewal, immune privilege, immunoregulation, and low tumorigenicity.

To date, mesenchymal stem cells have become the most commonly used cell type for treatment in clinical trials due to their safety, multidifferentiation potential, trophic activity, immunomodulatory properties, and abundant donor sources.

The MSCS type I myocardial regeneration drug we developed can effectively induce the expression of mesenchymal stem cells in clinical trials.

At the same time, because mesenchymal stem cells are from the patient's own body, they show better effects than traditional mesenchymal stem cell transplantation.

The left ventricular systolic function of patients after bone marrow mesenchymal stem cell transplantation only increased by 3-10%.

The implanted cells cannot survive for long periods of time. In fact, only about 24% of BMSCs are present in the border zone of the infarcted myocardium within 3 hours after transplantation, and less than 1% of BMSCs survive for more than a week [5].

More importantly, it is difficult for mesenchymal stem cells to differentiate into cardiomyocytes.

By using the MSCs I drug, the patient's left ventricular contraction function increased by 23%-37%. At the same time, after one week of continuous medication, more than 5% of bone marrow mesenchymal stem cells appeared in the edge area of ​​the infarcted myocardium.

The specific data on the differentiation of mesenchymal stem cells into cardiomyocytes is still being observed.

Critical steps of cell therapy procedures, such as in vitro expansion with donor selection, survival in the hostile transplantation microenvironment, migration, differentiation, and paracrine function, have been fully optimized.

Based on the existing clinical trial data, we can conclude that MSCS type I drugs have much superior therapeutic efficacy than traditional stem cell transplantation.

The attachment is a detailed phase report of the clinical trial."

It was a month later that Zheng Li finished reading the report. He was very happy staying at CERN.

Especially after being able to conduct research completely according to one's own wishes.

My understanding of the soul is much deeper than before.

"Alan, congratulations, you have made new achievements recently, and the sensational effect of this achievement is no less than that of the previous paper."

Kate tried to hint to Zheng Li many times, but never got the response she wanted.

Zheng Li did not show any intention of love between men and women at all. He would only say a few more words when Kate talked about research-related matters.

"In fact, people have always speculated about this discovery."

Kate felt a little depressed because the other party always managed to make a great discovery sound worthless.

It always seems like the other person is pretending to be awesome, but you can't see any signs of pretense on his face.

Kate was speechless and said: "If this is nothing, then other researchers in CERN have nothing to show for it.

All the papers I have published since I graduated with my PhD are not worth mentioning.”

Kate has been a top student since childhood, and has met many Nobel Prize winners at CERN.

In Kate's eyes, Zheng Li is a person with an extremely keen sense of smell and unlimited energy.

Other scientists with a keen sense of smell usually need to rest for a long time after studying a problem.

Kate had never seen someone like Zheng Li, who had just proved the existence of high-dimensional space and then started researching the next topic and successfully solved it.

Scientific research is not about the ability to do questions, but the ability to solve problems.

Of course, there are people who can do scientific research like doing homework, but that kind of scientific research does not have much meaning.

Utilitarian research such as publishing papers just for the sake of publishing papers can only be said to be a matter of personal opinion.

"I knew you could win this year's Nobel Prize. Now it seems that you are likely to win it alone."

“We have always suspected that even when intelligent life is alive, soul particles are escaping.

But there is a long distance between speculation and confirmation.

You just walked this distance.

No one could disprove the Goldbach conjecture, and when it was finally proven, it was no small matter. "

While Zheng Li was using CERN equipment to do private work for his own research, he also threw out some of the incidental research results.

The European Union is delighted with Zheng Li's discovery and believes that it has immeasurable value.

When they were discussing among themselves, they all expressed admiration for Higgs' amazing vision and that the successor he chose was even better than they had expected.

Alan is only about 40 years old, and with the bonus of the magic brain, it means that he can be in charge of CERN for the next 40 years.

Different social organizations have different functions, and the heads of top scientific research institutions generally do not change frequently, and it is best if they can remain stable for a long time.

They were sad because similar guesses had already been submitted in the magic forum, and once the guess was confirmed, they would not be able to obtain magic coins again by submitting it again.

"Well, that's the past and we need to look forward," Zheng Li said.

Kate asked: "Would you like to travel and relax?
We can go to the beach. In summer, we should go to the beach to relax!

Life should not be just about work. I feel like you are overworked and need some time to breathe."

Zheng Li thought: Are you crazy? I have only been the head of CERN for less than half a year, and you want me to take a rest?
There are so many things I want to do, so I don’t have the time to travel. What’s so interesting about the seaside? Is it more interesting than the image of particle movement?

I watch the sea on Clark Island every day and I'm tired of it.

"No, no, no, you misunderstood. I'm not in a state of panic. In fact, I'm in good shape. It's rare for me to have such a fulfilling life.

If you need a break, I'll give you some time off."

In fact, the contradiction lies in whether you enjoy your work. If work can bring you happiness, you will not be particularly sensitive to taking a vacation.

Generally, those who are sensitive to vacations are workers, as everyone works for income.

Bosses are not sensitive to holidays at all, and entrepreneurs often publicly advertise that they work all year round. Their working all year round is completely different from that of employees.

First of all, they work for themselves and have a natural self-motivation. Watching a project or a company grow from zero to one brings a sense of accomplishment that cannot be matched by working people.

In addition, they have control over their time, which can optimize the allocation of personal energy and achieve the greatest degree of happiness.

After saying that, Kate fell silent. She held her forehead and thought: No wonder Alan is still unmarried at the age of 40.

(End of this chapter)